Dermatomyositis Autoantibody Panel
May be useful for evaluation of patients with characteristic cutaneous manifestations of dermatomyositis with or without muscle weakness.
Qualitative Immunoprecipitation/Qualitative Immunoblot
New York DOH Approval Status
Serum Separator Tube (SST).
Separate from cells ASAP or within 2 hours of collection. Transfer one 1 mL serum aliquots to ARUP Standard Transport Tubes. (Min: 0.5 mL/aliquot)
Hemolyzed, hyperlipemic, icteric, heat-treated or contaminated specimens.
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year
|Mi-2 (nuclear helicase protein) Antibody||Negative|
|SAE1 (SUMO activating enzyme) Ab||Negative|
|MDA5 (CADM-140) Ab||Negative|
|NXP2 (Nuclear matrix protein-2) Ab||Negative|
|TIF-1 gamma (155 kDa) Ab||Negative|
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
Antibodies: Mi-2, P155/140, SAE1, MDA5, NXP2, TIF1-gamma
83516 x2; 84182 x4
|Component Test Code*||Component Chart Name||LOINC|
|2010852||Mi-2 (nuclear helicase protein) Antibody||18485-3|
|2013996||Dermatomyositis Interpretive Information||48767-8|
|3001786||SAE1 (SUMO activating enzyme) Ab||82440-9|
|3001787||MDA5 (CADM-140) Ab||82424-3|
|3001788||NXP2 (Nuclear matrix protein-2) Ab||82426-8|
|3001789||TIF-1 gamma (155 kDa) Ab||82448-2|